Respiratory Delivery of Gemcitabine for the Treatment of Lung Cancer

Register Free: https://www.pharmtech.com/pt_w/gemcitabine

Event Overview:

Respiratory drug delivery relies heavily on particle engineering to control delivery of pharmaceuticals to target tissues. Process selection becomes even more crucial when supporting novel formulation approaches to drug delivery to the lungs. The speakers Bryce Beverlin II (Quench Medical) and Maureen Kadleck (Lonza Small Molecules) will use the case study of an Excipient Enhanced Growth for gemcitabine as an inhaled lung cancer treatment to illustrate a pathway from feasibility studies through scale-up to commercialization. There will be an emphasis on process design choices using traditional particle engineering approaches, and the new process capabilities needed to achieve the desired target product profile.

Key Learning Objectives:

• Gain an understanding of the excipient enhanced growth platform
• Find out more about spray drying scale-up and lifecycle

Who Should Attend:

-Pharmaceutical directors

-Formulation scientists

-Manufacturing engineers

-Anyone interested in learning about the excipient enhanced growth platform or spray drying scale-up

For any questions please contact Jordan Ramesh: jramesh@mjhlifesciences.com

Speakers

Maureen Kadleck
Product Development Engineer and Project Lead
Lonza

Maureen is part of the Inhalation Technology Product Development Team at Lonza and has spent her four years with the company focusing on late-stage clinical projects, readying them for registration and process validation. She has taken projects through successful scale up and risk assessment processes across multiple platforms, including spray drying, encapsulation, twin-screw extrusion and fluid bed coating. Most recently, she has been focused on inhalation formulation development for small molecules and biologics.

Prior to joining Lonza, Maureen spent seven years with the Dow Chemical Company, where she held manufacturing and improvement engineering roles supporting multistep synthesis and purification processes. During her time with the company, she supported multi-million dollar capital expansion projects, earned a Six Sigma Green Belt, and chaired the young engineers network at the site. Maureen earned a chemical engineering degree from Northwestern University.

Bryce Beverlin II
CEO
Quench Medical

Bryce Beverlin II, PhD, founded Quench Medical to solve crucial problems in respiratory drug delivery for treating lung diseases. As CEO of Quench Medical, he is driven by a passion to help patients with lung diseases by developing the next generation of highly performing inhaled treatments. Bryce is a physicist entrepreneur with 15 years of cross-functional R&D experience, postdoctoral commercialization training at the University of Minnesota's Medical Devices Center, biomedical engineering training, and a physics PhD from the University of Minnesota.

Register Free: https://www.pharmtech.com/pt_w/gemcitabine